

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 3681)**

## **FURTHER DELAY IN DESPATCH OF CIRCULAR RELATING TO CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS**

Reference is made to (i) the announcements of the SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”) dated 17 September 2021 in relation to, among other things, the Supplemental Agreement to the BTK Transfer and Collaboration Agreement and the License Agreement; and (ii) the announcement of the Company dated 12 October 2021 in relation to delay in despatch of circular relating to connected transaction and continuing connected transactions (the “**Announcements**”). Unless the context otherwise requires, capitalised terms used in this announcement shall bear the same meanings as defined in the Announcements.

As disclosed in the Announcements, a circular containing, among others, further details of (i) the Supplemental Agreement and the License Agreement and the transactions contemplated thereunder; (ii) a letter of recommendations from the independent Board committee to the independent Shareholders in respect of the Supplemental Agreement and the License Agreement; (iii) a letter of advice from the independent financial adviser to the independent Board committee and the independent Shareholders in respect of the Supplemental Agreement and the License Agreement; and (iv) a notice convening the extraordinary general meeting, will be despatched to the Shareholders on or before 29 October 2021.

As additional time is required for the Company to prepare and finalise the information included in the circular, the circular is expected to be despatched to the Shareholders on or before 30 November 2021.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 29 October 2021

*As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.*